NeuroOne Granted 180-Day Extension to Regain Nasdaq Minimum Bid Price Compliance

NeuroOne Medical Technologies Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company now has until May 4, 2026, to maintain a minimum bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2). This extension provides NeuroOne additional time to address the stock price deficiency that had placed its Nasdaq listing status at risk.

The extension follows the company's previous notification from Nasdaq regarding non-compliance with the minimum bid price requirement for 30 consecutive business days. NeuroOne had initially been given until November 3, 2025, to regain compliance but was unable to meet the requirement within that timeframe. The company formally advised Nasdaq of its intention to cure the deficiency during the newly granted extension period, which has no immediate effect on the current listing status of NeuroOne's common stock.

NeuroOne will continue monitoring its stock's closing bid price and working toward compliance during the extension period. Failure to meet the minimum bid price requirement by the May 2026 deadline could result in delisting proceedings, though the company would retain the right to appeal any delisting determination to a Nasdaq Hearing Panel. The company acknowledges there is no guarantee that such an appeal would be successful if needed.

As a medical technology company focused on neurological disorders, NeuroOne develops minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. Additional information about the company's technologies and development programs can be found at https://nmtc1.com. The extension provides NeuroOne crucial time to implement strategies that may help restore investor confidence and stabilize its market position while continuing its medical technology development efforts.